CAMBRIDGE, Mass., May 22, 2024
/PRNewswire/ -- GV20 Therapeutics, a clinical-stage biotechnology
company integrating AI, genomics, and disease biology to create
next-generation antibody therapeutics for cancer, announced today
that it will present at the Jefferies Global Healthcare Conference
Private Biotech Day, taking place June 4th,
2024, in New York.
Company management will be conducting one-on-one meetings with
investors at the conference.
ABOUT GV20 THERAPEUTICS
At GV20 Therapeutics, our mission is to develop a differentiated
pipeline of innovative antibody therapeutics to transform cancer
treatment. We leverage our in-house STEAD platform (Simultaneous
Target Evaluation and Antibody Discovery), which integrates AI,
genomics, and disease biology to identify novel drug targets and
create next-generation therapies against these targets. Our lead
program, GV20-0251, is a first-in-class, fully human, Fc-attenuated
IgG1 monoclonal antibody targeting a novel innate immune checkpoint
IGSF8. The GV20-0251-100 multi-center Phase I clinical trial in
patients with advanced solid tumors (NCT05669430) is the first
clinical study of an AI-designed antibody against an AI-predicted
target. GV20 is headquartered in Cambridge, MA.
To learn more about GV20, please visit https://gv20tx.com/ and
follow the company on LinkedIn.
Business Contact
Ying Gong,
Ph.D., CBO
BD@gv20tx.com
Investor and Media Contact
Amy
Conrad
Juniper Point
amy@juniper-point.com
View original
content:https://www.prnewswire.com/news-releases/gv20-therapeutics-to-present-at-the-jefferies-healthcare-conference-private-biotech-day-302152897.html
SOURCE GV20 Therapeutics